Hyperion Therapeutics major shareholder Scott D. Sandell Unloads 1,430 Shares (HPTX)
Hyperion Therapeutics (NASDAQ:HPTX) major shareholder Scott D. Sandell sold 1,430 shares of Hyperion Therapeutics stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $5.54, for a total value of $7,922.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Hyperion Therapeutics (NASDAQ:HPTX) opened at 26.00 on Wednesday. Hyperion Therapeutics has a 1-year low of $18.97 and a 1-year high of $32.98. The stock’s 50-day moving average is $25.99 and its 200-day moving average is $25.81. The company has a market cap of $526.9 million and a P/E ratio of 21.04.
Hyperion Therapeutics (NASDAQ:HPTX) last announced its earnings results on Tuesday, May 6th. The company reported $0.06 earnings per share (EPS) for the quarter. On average, analysts predict that Hyperion Therapeutics will post $-0.23 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Hyperion Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Tuesday, April 29th. They now have a $25.20 price target on the stock. Analysts at Cantor Fitzgerald initiated coverage on shares of Hyperion Therapeutics in a research note on Tuesday, March 18th. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating and three have given a buy rating to the stock. Hyperion Therapeutics has a consensus rating of “Buy” and a consensus price target of $34.84.
Hyperion Therapeutics, Inc (NASDAQ:HPTX)is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.